Meghan FitzGerald - 12 Sep 2023 Form 4 Insider Report for Roivant Sciences Ltd. (ROIV)

Role: Director
Signature: By: /s/ Jo Chen, as Attorney-in-Fact for Meghan Fitzgerald
Issuer symbol: ROIV
Transactions as of: 12 Sep 2023
Net transactions value: $0
Form type: 4
Filing time: 14 Sep 2023, 21:31:13 UTC
Previous filing: 06 Jul 2023
Next filing: 18 Oct 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ROIV	Common Shares	Award	$0	+8,937	+776%	$0.000000	10,089	12 Sep 2023	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ROIV	Stock Option (Right to Buy)	Award	$0	+13,334		$0.000000	13,334	12 Sep 2023	Common Shares	13,334	$11.22	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Reflects an annual award of restricted stock units with respect to Common Shares ("RSUs") granted pursuant to the Company's 2021 Equity Incentive Plan and the Company's Non-Employee Director Compensation Policy. The award of RSUs is scheduled to vest 100% on September 12, 2024, subject generally to the reporting person's continuous service through such date.
F2	Reflects an annual award of stock options to purchase Common Shares granted pursuant to the Company's 2021 Equity Incentive Plan and the Company's Non-Employee Director Compensation Policy. The award of stock options is scheduled to vest and become exercisable 100% on September 12, 2024, subject generally to the reporting person's continuous service through such date.